HCP Inc. upgraded to Buy from Hold at Jefferies Jefferies upgraded HCP Inc. citing valuation and upside potential from accretive deal activity. The firm lowered its price target for shares to $41 from $43.
HCP downgraded at Morgan Stanley As previously reported, Morgan Stanley downgraded HCP (HCP) to Equal Weight from Overweight. The analyst said improving rent coverage at its largest tenant, HCR Manor Care, has been pushed out to 2016 and believes shares lack near-term catalysts. Price target lowered to $45 from $50.